# Thermo Fisher Scientific account plan

> Thermo Fisher Scientific sells lab instruments, consumables and drug development services, with FY2025 revenues of $44,556 million and about 125,000 staff.

## At a glance

Thermo Fisher Scientific, based in Waltham, Massachusetts, sells instruments, reagents, consumables, lab supplies and outsourced drug development and manufacturing services under brands including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Patheon and PPD. Its customers are pharma and biotech companies, hospitals and diagnostic labs, universities, government agencies and industrial labs; pharma and biotech is about 60% of revenue. FY2025 revenues were $44,556 million (+4%, organic +2%), with GAAP operating income of $7,746 million and net income attributable of $6,704 million. It had approximately 125,000 colleagues at December 31, 2025, including approximately 14,000 sales personnel. North America generated $23,033 million of 2025 revenue.

## Business units

- **Laboratory Products and Biopharma Services** (about 53% of FY2025 revenue ($23,984 million before eliminations, computed)): Lab supplies through the Fisher Scientific research and safety market channel, laboratory products, clinical research (PPD, now with Clario) and pharma services (Patheon) for drug development and manufacturing. Q2 2026 revenue rose 12% to $6,693 million, with Clario adding $441 million of clinical research growth. Mike Shafer leads Biopharma Services.
- **Life Sciences Solutions** (about 20% of FY2025 revenue ($10,374 million before eliminations, computed)): Reagents, instruments and consumables for biological research and drug production across biosciences, BioProduction and genetic sciences (including Olink proteomics). It had the highest segment margin, 36.3% in 2025 and 37.0% in Q2 2026, when revenue rose 13% to $2,815 million led by bioproduction and the Solventum filtration acquisition.
- **Analytical Instruments** (about 17% of FY2025 revenue ($7,554 million before eliminations, computed)): Chromatography and mass spectrometry, electron microscopy and chemical analysis instruments with consumables, software and services for pharma, academic, industrial and semiconductor customers. Margin fell to 23.0% in 2025 on tariffs, then recovered 4.2 pt to 23.0% in Q2 2026 on 7% revenue growth.
- **Specialty Diagnostics** (about 10% of FY2025 revenue ($4,676 million before eliminations, computed)): Diagnostic test kits, reagents, culture media and instruments across the healthcare market channel, clinical diagnostics, immunodiagnostics, microbiology and transplant diagnostics. Q2 2026 revenue rose 6% to $1,205 million; the microbiology business is being sold to Astorg.

## Strategic priorities

- **Three-pillar growth strategy**: High-impact innovation, trusted partner status with customers and the commercial engine, backed by the PPI Business System for productivity.
- **Long-term growth targets**: At the May 2026 Investor Day: 3-6% organic growth with 50-70 bps margin expansion for 2026-2027, and a 7% organic revenue CAGR with 40-50 bps annual margin expansion for 2028-2031+.
- **AI across science and operations**: Collaborations with OpenAI (clinical research) and NVIDIA, and AI inside PPI for customer care, R&D and operations; management says "AI will accelerate science and benefit our industry, we are uniquely positioned to win".
- **Integrated drug development offering**: The Accelerator offering combines CDMO, CRO, clinical endpoints and clinical trial supplies, with biotech customers the main adopters.
- **U.S. reshoring capacity**: Flexible CDMO capacity, outfitting customers' new plants and the Sanofi Ridgefield, NJ sterile fill finish site, against $500B+ of U.S. biopharma reshoring commitments.
- **M&A-led capital deployment**: 60-75% of capital to M&A and 25-40% to return of capital over time; more than $70B deployed since 2012.

## Latest results

In Q2 2026 (quarter ended June 27, 2026) revenues rose 10% to $11,994 million, with organic growth of 5% and acquisitions adding 5%. Adjusted operating margin was 22.8% (+0.9 pt) and adjusted EPS rose 13% to $6.03. All end markets grew, with pharma and biotech up mid-single digits, academic and government back to low-single-digit growth and China returning to growth. First-half revenues were $22,999 million (+8%). Full-year 2026 guidance was raised to revenue of $47.4 billion-$48.1 billion, organic growth of about 4% and adjusted EPS of $24.93-$25.33.

## Investments and deals

- **Clario acquisition**: Acquired on March 24, 2026 for a purchase price of $9,098 million; Clario provides endpoint data solutions for clinical trials (~$1.25B of 2025 revenue) and targets $175M of synergies by year 5.
- **Solventum filtration and separation**: Acquired September 1, 2025 (cash paid $3,944 million); ~$750M of 2025 pro forma revenue and ~$125M of synergies by year five, extending BioProduction.
- **Microbiology divestiture**: Agreed on April 27, 2026 to sell the microbiology business to Astorg for approximately $1.075 billion, closing expected in Q3 2026.
- **Capex and new facilities**: 2026 capex expected at $1.9 billion to $2.1 billion, higher for U.S. manufacturing; a U.S. Bioprocess Design Center opened in Massachusetts and filtration capacity is being increased.
- **Share buybacks**: $4.00 billion of stock repurchased in H1 2026, including a $1 billion buyback funded in advance by expected microbiology proceeds.

## Challenges and risks

- **Tariffs and trade**: Tariffs and related FX cost over 100 basis points of margin in 2025; Analytical Instruments margin fell 320 basis points to 23%.
- **Academic and government funding**: Academic and government demand declined in 2025 on U.S. customer hesitancy and China macro conditions; Casper expects "a flat to slightly up NIH budget".
- **China**: China declined mid-single digits in 2025, and the 10-K names Chinese regulations requiring the use of local suppliers as a risk.
- **Indebtedness**: Total debt rose to $42,549 million at June 27, 2026 against cash of $4,064 million, and net interest expense nearly doubled to $194 million in Q2.
- **Pharma services quality and drug pricing policy**: Pharma services are "highly exacting and complex", and the Inflation Reduction Act's drug price negotiation could hit customers.

## What leadership says

> "We are actively deploying AI across the company to further accelerate PPI's impact." — Marc Casper, Chairman and CEO, Q2 2026 earnings call, 23 July 2026

> "We continue to have an active pipeline of M&A opportunities in our highly fragmented industry." — Marc Casper, Chairman and CEO, Q2 2026 earnings call, 23 July 2026

> "the more confidence you have in the research, you wind up doing actually more wet lab experimentation" — Marc Casper, Chairman, President and CEO, Q4 and full-year 2025 earnings call, 29 January 2026

> "if you have really relevant innovation, customers get money." — Marc Casper, Chairman and CEO, Q2 2026 earnings call, 23 July 2026


## Where a supplier can help

- **Manufacturing capacity build-out**: Higher 2026 capex for U.S. manufacturing, reshoring CDMO capacity and filtration expansion create demand for equipment, construction and validation suppliers.
- **AI and productivity in PPI**: The push to deploy AI across PPI for customer care, R&D and operations fits AI, automation and digital-twin vendors.
- **Integration of Clario and Solventum**: Synergy targets of $175M (Clario) and ~$125M (Solventum) point to integration, systems consolidation and commercial enablement services.
- **Trade and supply-chain resilience**: Tariff costs and China local-supplier rules open angles for sourcing, trade compliance and low-cost-region manufacturing partners.
- **Digital commerce for the lab channel**: With AI agents and personalised marketing on thermofisher.com and fishersci.com as part of the commercial engine, e-commerce and marketing technology providers have an entry point.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Form 10-K for fiscal year 2025](https://www.sec.gov/Archives/edgar/data/97745/000009774526000018/tmo-20251231.htm)

Annual report · 2026-02-26

- Thermo Fisher Scientific (Waltham, Massachusetts) describes itself as "the world leader in serving science"; it sells instruments, reagents, consumables, lab supplies and outsourced drug development and manufacturing services under brands including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. Approximately 125,000 colleagues at December 31, 2025 and approximately 14,000 sales personnel.
- FY2025 revenues of $44,556 million (+4%, organic +2%); GAAP operating income $7,746 million (17.4% margin); adjusted operating income $10,109 million (22.7%); GAAP diluted EPS $17.74, adjusted EPS $22.87; net income attributable $6,704 million; free cash flow $6,337 million.
- Four segments: Laboratory Products and Biopharma Services ($23,984 million, the largest, with clinical research (PPD), pharma services (Patheon) and the research and safety market channel), Life Sciences Solutions ($10,374 million, 36.3% segment margin, led by bioproduction), Analytical Instruments ($7,554 million) and Specialty Diagnostics ($4,676 million).
- 2025 end markets: pharma and biotech grew, academic and government declined on U.S. customer hesitancy and China macro conditions, industrial and applied grew, diagnostics and healthcare flat; China declined while North America, Europe and Asia-Pacific grew.
- Revenue mix 2025: consumables $18,664 million, services $18,592 million, instruments $7,301 million; North America $23,033 million, Europe $11,826 million, Asia-Pacific $8,101 million.
- M&A: Solventum's filtration and separation business acquired September 1, 2025 (cash paid $3,944 million); agreement to buy Clario Holdings (endpoint data for clinical trials) for approximately $8.875 billion in cash plus deferred and contingent consideration, to join Laboratory Products and Biopharma Services.
- Capital: total debt $39,384 million and cash of $9,852 million at year-end; $3.00 billion of buybacks in 2025 and another $3.00 billion early in Q1 2026; 2026 capex expected at $1.8 billion to $2.0 billion.
- Growth strategy has three pillars: high-impact innovation, trusted partner status with customers, and the commercial engine; productivity comes from the PPI (Practical Process Improvement) Business System. Main risks: customer capital spending and government funding, tariffs and trade, China local-supplier rules, pharma services quality, cyber-attacks and $39.38 billion of indebtedness.

### [Form 10-Q for the quarter ended June 27, 2026](https://www.sec.gov/Archives/edgar/data/97745/000009774526000144/tmo-20260627.htm)

Interim report · 2026-07-31

- Q2 2026 (quarter ended June 27, 2026): revenues $11,994 million, +10% (organic +5%, acquisitions +5%); GAAP operating income $2,087 million (17.4% margin); adjusted operating income $2,735 million (22.8%, +0.9 pt); GAAP diluted EPS $4.68 (+9%); adjusted EPS $6.03 (+13%).
- First half 2026: revenues $22,999 million (+8%, organic +3%); adjusted EPS $11.47 (+9%); free cash flow $2,503 million (H1 2025: $1,479 million).
- "Customer activity continued to strengthen across our end markets": strong growth in pharma and biotech, growth in academic and government, strong industrial and applied and diagnostics and healthcare; strong growth in Europe and Asia-Pacific, including China.
- Segments in Q2: Life Sciences Solutions $2,815 million (+13%, margin 37.0%, bioproduction-led); Analytical Instruments $1,847 million (+7% organic, margin up 4.2 pt to 23.0%); Specialty Diagnostics $1,205 million (+6%); Laboratory Products and Biopharma Services $6,693 million (+12%, Clario added $441 million of clinical research growth).
- Clario Holdings acquired on March 24, 2026 for a purchase price of $9,098 million (including $3,180 million of debt settled); two proteomics software companies also bought in 2026.
- Agreement on April 27, 2026 to sell the microbiology business (Specialty Diagnostics) to Astorg for approximately $1.075 billion, expected to close in Q3 2026.
- Balance sheet: cash $4,064 million, total debt $42,549 million; $4.00 billion of buybacks in H1 2026; 2026 capex expected at $1.9 billion to $2.1 billion; GAAP tax rate expected between 9% and 11%.

### [Q2 2026 earnings conference call transcript](https://www.marketbeat.com/earnings/reports/2026-7-23-thermo-fisher-scientific-inc-stock/)

Executive talk · Marc Casper, Chairman and Chief Executive Officer · 2026-07-23

- Marc Casper (Chairman and CEO) and new CFO Jim Meyer presented Q2 2026 on July 23, 2026: revenue +10% to $11.99 billion, organic +5%, adjusted operating margin 22.8% (+90 basis points), adjusted EPS +13% to $6.03.
- Guidance raised: revenue $47.4 billion-$48.1 billion (6%-8% reported growth), organic growth about 4% (upper end of 3%-4%), adjusted EPS $24.93-$25.33 (9%-11% growth); free cash flow $6.9 billion-$7.4 billion; acquisitions to add $1.6 billion of revenue and $0.32 of adjusted EPS.
- End markets all improved: pharma and biotech mid-single digits (about 60% of revenue), academic and government back to low-single-digit growth, industrial and applied and diagnostics mid-single digits. China (about 7.5% of revenue) returned to low-single-digit growth.
- Clario's first full quarter was "very strong" and the revenue-synergy funnel is "building nicely"; clinical research had strong organic growth in revenue and authorizations.
- Microbiology divestiture (2025 revenue $645 million) to close in Q3; its expected net proceeds were used early for a $1 billion buyback in Q2; dilution of about $0.15 of adjusted EPS in the first full year.
- Innovation: new Orbitrap Tribrid Apex and Excedion mass spectrometers, Vanquish Amplify UHPLC and the Applied Biosystems PowerFlex thermal cycler; a U.S. Bioprocess Design Center opened in Massachusetts.
- Casper on AI and pharma: "We are actively deploying AI across the company to further accelerate PPI's impact"; large pharma customers "have their arms around the macro", including IRA, MFN and tariffs.

### [Q4 and full-year 2025 earnings conference call transcript](https://www.marketbeat.com/earnings/reports/2026-1-29-thermo-fisher-scientific-inc-stock/)

Executive talk · Marc Casper, Chairman, President and Chief Executive Officer · 2026-01-29

- Marc Casper (Chairman, President and CEO) and CFO Stephen Williamson presented Q4 and full-year 2025 on January 29, 2026: Q4 revenue +7% to $12.21 billion, adjusted EPS +8% to $6.57; FY2025 revenue $44.56 billion (+4%, organic +2%), adjusted EPS $22.87 (+5%).
- Initial 2026 guidance: revenue $46.3 billion-$47.2 billion, organic growth 3%-4%, adjusted EPS $24.22-$24.80 (6%-8% growth), excluding Clario; free cash flow $6.8 billion-$7.3 billion; $3 billion of buybacks completed in January.
- Capital deployed in 2025: approximately $16.5 billion, including $13 billion committed to M&A (Solventum filtration, Sanofi's New Jersey sterile fill finish site, Clario) and $3.6 billion returned to shareholders.
- Clario (about $1.25 billion of 2025 revenue) was expected to add about $0.45 of adjusted EPS in its first 12 months and to close by mid-2026.
- Tariffs and related FX cost over 100 basis points of margin in 2025; Analytical Instruments margin fell 320 basis points to 23%.
- AI: strategic collaboration with OpenAI (focused on clinical research) and an NVIDIA collaboration; Casper argues more confidence in research means more wet lab experimentation, not less.
- Stephen Williamson retires at the end of March 2026; Jim Meyer, 17 years at the company, becomes CFO.

### [2026 Investor Day presentation](https://s25.q4cdn.com/974941731/files/doc_downloads/Downloads/2026-Investor-Day-Presentation-Distribution.pdf)

Report · 2026-05-20

- Thermo Fisher's 2026 Investor Day (New York, May 20, 2026) was presented by Marc Casper (Chairman and CEO), Gianluca Pettiti (President and COO since March 2026), Mike Shafer (EVP, Biopharma Services) and CFO Jim Meyer.
- New long-term targets: 7% long-term organic revenue CAGR (2028-2031+), 40-50 bps annual margin expansion, low-teens adjusted EPS and free cash flow growth. Mid-term framing for 2026-2027: 3-6% organic growth, 50-70 bps margin expansion, high single-digit adjusted operating income growth.
- Scale on LTM to Q1 2026: $45B revenue, >125,000 colleagues, $1.4B R&D; 57% pharma & biotech, 84% services and consumables, 51% North America; served market sized at $255B.
- Segments (LTM before eliminations): Laboratory Products & Biopharma Services $24.4B, Life Sciences Solutions $10.7B, Analytical Instruments $7.6B, Specialty Diagnostics $4.7B.
- AI framed as a tailwind: higher R&D returns lead customers to reinvest in pipelines; collaborations with NVIDIA and OpenAI; AI is used inside the PPI Business System for customer care, R&D and operations.
- Acquisitions: Clario (~$1.25B 2025 revenue, $175M of synergies by year 5, $0.32 accretive to 2026 adjusted EPS); Solventum purification and filtration (~$750M pro forma revenue, ~$125M of synergies by year five). BioProduction is a $3.4B business.
- Capital deployment over time: 60-75% to M&A, 25-40% to return of capital; more than $70B deployed since 2012. 2026 guidance at the time: revenue $47.3B-$48.1B, adjusted EPS $24.64-$25.12.

## Questions about Thermo Fisher Scientific

### What does Thermo Fisher Scientific do?

It sells lab instruments, reagents, consumables and supplies, diagnostics, and outsourced clinical research and drug manufacturing services to pharma, biotech, healthcare, academic, government and industrial customers.

### What was Thermo Fisher Scientific's revenue?

FY2025 revenues were $44,556 million (+4%). 2026 guidance, raised in July 2026, is $47.4 billion-$48.1 billion.

### How many employees does Thermo Fisher Scientific have?

Approximately 125,000 colleagues at December 31, 2025, including approximately 14,000 sales personnel.

### What is Thermo Fisher Scientific's strategy?

Growth through high-impact innovation, trusted partner status and its commercial engine, productivity from the PPI Business System, and capital deployed mainly through M&A, with a long-term 7% organic growth target.

### Who leads Thermo Fisher Scientific?

Marc Casper is Chairman and CEO; Gianluca Pettiti became President and COO and Jim Meyer CFO in March 2026.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
